CAS 854001-07-3

Dasatinib hydrochloride

CAS: 854001-07-3

Dasatinib hydrochloride

Reinheit: ≥98%

Molekulargewicht: 524.47g/mol

Ref: 54-BUP14631

Dasatinib hydrochloride

CAS: 854001-07-3

Dasatinib is a tyrosine kinase inhibitor that inhibits the activity of several receptor tyrosine kinases, including c-Kit, PDGFRA, and PDGFRB. Dasatinib was developed for the treatment of acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and other cancers. It is marketed in capsule form as a solution for oral administration. Dasatinib is insoluble in water but soluble in aqueous solutions with pH below 7.5. Dasatinib has been shown to be effective against liposome-encapsulated cancer cells, which may be due to its inhibition of extracellular liposomes.

Formel: C₂₂H₂₇Cl₂N₇O₂S

Reinheit: Min. 95%

Molekulargewicht: 524.47 g/mol

Ref: 3D-EJB00107

Dasatinib hydrochloride

CAS: 854001-07-3

Formel: C₂₂H₂₆N₇O₂SHCl

Molekulargewicht: 488.01 : 36.46

Ref: ST-EA-CP-D1057

Dasatinib hydrochloride

CAS: 854001-07-3

Dasatinib hydrochloride is an oral Src/Bcr-Abl inhibitor with potent antitumor effects, Ki values of 16 pM (Src) and 30 pM (Bcr-Abl).

Formel: C₂₂H₂₇Cl₂N₇O₂S

Reinheit: 99.88% - 99.98%

Farbe und Form: Solid

Molekulargewicht: 524.47

Ref: TM-T22303